EORTC Receptor and Biomarker Study Group Report: A Sandwich Enzyme-Linked Immunosorbent Assay for Vascular Endothelial Growth Factor in Blood and Tumor Tissue Extracts
Open Access
- 1 April 2000
- journal article
- research article
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 15 (2) , 184-191
- https://doi.org/10.1177/172460080001500210
Abstract
A four-antibody sandwich enzyme-linked immunosorbent assay (ELISA) for vascular endothelial growth factor (VEGF) for application in blood (serum and plasma) and tumor tissue extracts was set up within the framework of the EORTC Receptor and Biomarker Study Group (RBSG). Polyclonal antibodies against VEGF165 were raised in chickens and rabbits, and used in a previously described assay format. The assay was validated and characterized for use in serum, plasma and tumor tissue extracts. The resulting VEGF ELISA was found to be specific for VEGF165 and VEGF121, the main isoforms of VEGF. The assay showed good precision and parallelism in serial dilutions of samples. The assay was not susceptible to interference by heterophilic antibodies because avian antibodies (duck anti-chicken and chicken anti-VEGF) were used in the pre-analyte stage and mammalian antibodies (rabbit anti-VEGF and goat anti-rabbit) in the post-analyte stage. In conclusion, a sensitive, robust and specific VEGF ELISA has been developed. Research into the prognostic value of VEGF employing this assay is currently underway.Keywords
This publication has 28 references indexed in Scilit:
- VASCULAR ENDOTHELIAL GROWTH FACTOR AS PROGNOSTIC FACTOR IN RENAL CELL CARCINOMAJournal of Urology, 2000
- Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinomaCancer, 1999
- Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant diseaseCancer, 1999
- Vascular endothelial growth factor (VEGF) and its receptorsThe FASEB Journal, 1999
- Clinical significance of angiogenic factors in breast cancerBreast Cancer Research and Treatment, 1998
- High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancerInternational Journal of Cancer, 1998
- Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biologyBritish Journal of Cancer, 1998
- Angiogenesis and Tumor MetastasisAnnual Review of Medicine, 1998
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995
- Angiogenic FactorsScience, 1987